Figure 3.

Prophylactic efficacy of 54G10 in mice. A, Prophylactic 54G10 does not decrease virus titer in the nasal turbinates (NTs) of human metapneumovirus (HMPV) A2–infected mice, compared with control. B, Prophylactic 54G10 decreases peak virus titer in the lungs of HMPV A2–infected mice (***P < .001). C, 54G10 prophylaxis decreases virus titer in the NTs of mice infected with HMPV B2 (**P = .01). D, All mice that received 54G10 prophylaxis had a decrease in lung titer, regardless of the HMPV subgroup (***P < .001). Virus titer was log₁₀ transformed and analyzed by the Student t test, with 3–5 mice per group. E, Pulmonary histopathologic findings by hematoxylin-eosin staining on day 7 of mice that received 54G10 prophylaxis and were infected with HMPV A2 demonstrate preservation of airway spaces. Images are 100× the original magnification. Abbreviations: PBS, phosphate-buffered saline; PFU, plaque-forming unit.